Jakarta: Indonesia will receive raw materials vaccine in bulk form from Sinovac manufacturer. PT Bio Farma will produce this raw material into a complete vaccine.
“We’ve been working together and we have agreement Sinovac, there are approximately 140 million doses of raw materials that will immediately enter according to timeline to Indonesia, “said Honesti Basyir, President Director of PT Bio Farma in a televideo conference, Tuesday, February 16, 2021.
PT Bio Farma has produced 15 million vaccines covid-19. Meanwhile, the Food and Drug Supervisory Agency (BPOM) has issued an emergency use permit or emergency use authorization (EUA) against vaccines made by Bio Farma. Thus, as many as 7.5 million doses of the vaccine dubbed the ‘covid-19 vaccine’ were distributed in February 2021.
<!–
<!–
–
–
–
–
–
–>
What do you think of this article?
–
–
Honesti welcomes the publication of EUA on the vaccine produced by Bio Farma. He hopes that this permit will accelerate the covid-19 vaccination program in Indonesia.
“It becomes something milestone new to the Indonesian people, so we can accelerate the vaccination program, “said Honesti.
Read: BPOM Issues Permit for Emergency Use of Sinovac Vaccines for Domestic Production
The Ministry of Health (Kemenkes) will start the second phase of vaccination with a target of 38 million people on Wednesday, February 17, 2021. This stage is targeted to be completed by April 2021.
The government has also listed the groups that fall into the priority category for stage two vaccine administration. Other groups include the elderly (elderly), market traders, teaching staff or educators, religious leaders, representatives of the people, government officials, and the state civil apparatus (ASN).
Then, the security forces, tourism officials, public services, and public transportation workers. Athletes as well as journalists and media workers are also part of the priority for the second phase of the covid-19 vaccine.
(AZF)
– .
